Is the price fair?
What ZBH's price assumes
Zimmer Biomet trades at 26.3× earnings against 33.4× for the median Medical Devices name, cheaper than its own group.
26.3
Trailing P/E · Medical Devices median 33.4 · cheaper than the typical name in its group
- Price / sales
- 2.11
Price / sales · as of 2026-Q1
- Free cash flow yield
- 8.6%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- −1.5%
Growth the price implies · The price pays for −1.5% free cash flow growth a year for a decade; the business has delivered +8.2% a year over the last three.
Details›
- Price / book2026-Q1
- 1.40
- EV / EBIT2026-Q1
- 20.0
- EV / sales2026-Q1
- 2.80
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $1.46B
- Market capitalisation
- $17.0B
- 3-year revenue growth
- +5.8%
- 3-year free cash flow growth
- +8.2%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $91.40 |
| Its own P/E history, median | $154.33 |
| Its own P/E history, upper quartile | $260.66 |
| 52-week range | $79.58 – $106.87 |
| Today | $101.36 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
Ranks #14 of 35 by Smart Score